Therapy News and Research

RSS

Jennerex presents positive interim data from Phase 2 clinical trial of JX-594 for HCC at 45th EASL

Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today announced the presentation of positive interim data from its randomized Phase 2 clinical trial using JX-594 for the treatment of advanced hepatocellular carcinoma (HCC), or liver cancer, at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria.

19 Apr 2010

Smith & Nephew highlights advanced wound care product portfolio at 2010 SAWC/WHS meeting

The Advanced Wound Management division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew plc announced today that a total of 16 posters on studies conducted with its advanced wound care products were presented at this year's Symposium on Advanced Wound Care (SAWC) and Wound Healing Society (WHS) meeting.

19 Apr 2010

Healthyroads announces new partnership status with NAQC

Healthyroads, the wellness subsidiary of American Specialty Health Incorporated, announced its new partnership status with the North American Quitline Consortium and its approval to serve as an authorized quitline vendor in the state of Michigan.

19 Apr 2010

Methotrexate therapy not recommended beyond 6 months after remission: JAMA

For patients with juvenile idiopathic arthritis in remission, withdrawal of treatment with the drug methotrexate over 12 months vs. 6 months did not reduce the rate of relapse, according to a study in the April 7 issue of JAMA.

19 Apr 2010

Potential drug to annul ADAM-17 protein activity needed

Over the past four years, in the installations of the Faculty of Medicine, University of Cadiz, a group of researchers, headed by Doctor Carmen Estrada, has been studying neurogenesis - the process of forming new neurons from mother cells - in the adult mammal brain. The purpose of this research project is to contribute to the knowledge of this process with the object of finding some additional mechanism that would facilitate the treatment of pathologies of the central nervous system (CNS) that are suffered in consequence of neuronal death.

19 Apr 2010

Phase II study: Hepatitis C patients receiving ANA598 bid plus SOC attain undetectable levels of virus

Anadys Pharmaceuticals, Inc. announced today that 72% of hepatitis C patients receiving ANA598 400 mg twice daily (bid) plus standard of care achieved undetectable levels of virus at week eight in an ongoing Phase II study, compared to 38% of patients receiving placebo plus SOC.

19 Apr 2010

Surgery still the only measure to cure RCC

Renal cell carcinoma (RCC) accounts for about 3% of all solid tumours in adults, and worldwide, more than 200.000 new cases and 100.000 deaths result each year from this malignancy.

19 Apr 2010

Radiolabeled hedgehog can differentiate stem-like cancer cells, identify aggressive tumors

At the American Association for Cancer Research 101st Annual Meeting 2010, scientists and clinicians will present more than 6,300 abstracts dealing with innovative aspects of biology, technology and emerging therapies.

19 Apr 2010

Results of BATTLE Trial presented at AACR 2010

Lung cancer is the number one cause of cancer death in men and women, but huge randomized trials of thousands of patients have either failed completely or shown negligible survival differences.

19 Apr 2010

Cell Therapeutics receives feedback regarding proposed filing of MAA for pixantrone

Cell Therapeutics, Inc. today announced that it met with and received feedback from the rapporteurs and the European Medicines Agency's medical reviewers regarding a proposed filing of a Marketing Authorization Application for pixantrone in the European Union to treat relapsed/refractory aggressive non-Hodgkin's lymphoma.

19 Apr 2010

Data on ConvaTec's medical devices to be presented at SAWC/WHS 2010

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced that data related to several of its medical devices will be presented at the 23rd Annual Symposium on Advanced Wound Care and Wound Healing Society in Orlando, Florida from April 17th to April 20th, 2010.

19 Apr 2010

Results from Phase 2 study of BOTOX in IOAB patients presented at Anniversary EAU Congress

Treatment options for idiopathic OAB patients not adequately managed by anticholinergic therapy are limited; either highly invasive, expensive or of limited efficacy. BOTOX® (onabotulinumtoxinA) may provide a minimally invasive effective treatment. Professor Chris Chapple and his group conducted the first large, double-blind, placebo-controlled, dose ranging study to systematically asses the benefit/risk balance of the use of BOTOX® in IOAB across a wide range of doses.

19 Apr 2010

Enhancing drug residence time may help develop better diagnostic, therapeutic agents

Research conducted at the Stony Brook University Institute for Chemical Biology & Drug Discovery that enhances the time a drug remains bound to its target, or residence time, may prove to be an important step in developing better diagnostic and therapeutic agents based partly on longer drug residence time.

17 Apr 2010

MedImmune to present ten abstracts at American Association for Cancer Research meeting

MedImmune today announced that ten abstracts on progress being made in various oncology programs will be presented during the Annual Meeting of the American Association for Cancer Research in Washington, DC from April 17 to 21.

17 Apr 2010

MEDIHONEY dressings serve as low-cost method for treating wounds in indigent patients

Using a particular brand of medical honey dressing may be a safe, effective and low-cost method of treating chronic, non-healing wounds in indigent patients, according to a poster presented at the Symposium on Advanced Wound Care and the Wound Healing Society, an international conference drawing clinicians from all over the globe, which was held April 17-20 in Orlando.

17 Apr 2010

MEDIHONEY dressings effective in treating chronic wounds in children

Chronic, non-healing wounds can be a serious problem for children as many currently available treatment modalities can be too harsh or toxic. At the 2010 Symposium on Advanced Wound Care (SAWC) and the Wound Healing Society (WHS), an international conference drawing clinicians from all over the globe which was held April 17-20 in Orlando, two clinicians presented case series illustrating the benefits of MEDIHONEY® dressings for this challenging patient population.

17 Apr 2010

Access to NAbs testing important for MS therapy management

Teva Neuroscience today announced results at the 62nd American Academy of Neurology Annual Meeting which demonstrated that eliminating barriers to neutralizing antibodies (NAbs) testing significantly impacted multiple sclerosis (MS) treatment choices in patients receiving interferon beta (IFNβ) therapies.

17 Apr 2010

Extracorporeal liver support therapy valued as detoxification treatment option for patients with cirrhosis

Results from two studies presented today at the International Liver CongressTM 2010 have shown that treatment with extracorporeal devices may not confer a survival advantage for severe liver failure patients, despite positive dialysis effects. However, results among a small sub-group of patients show promise.

17 Apr 2010

NSF Faculty Early Career Development Award for Zhihao Zhuang

Zhihao Zhuang, assistant professor in the Department of Chemistry and Biochemistry at the University of Delaware, has won the National Science Foundation Faculty Early Career Development Award.

17 Apr 2010

G1 HCV patients having fast antiviral response to TVR with PEG-IFN and RBV can be cured in 24 weeks

24 weeks of treatment could be sufficient to cure between 93 and 100% of treatment-na-ve chronic hepatitis C virus (HCV) genotype 1 (G1) infected patients if they have a fast antiviral response to Telaprevir (TVR) with Peginterferon (PEG-IFN) and Ribavirin (RBV), according to new research presented today at the International Liver Congress 2010, the Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria.

17 Apr 2010

Therapy News and Research

Jennerex presents positive interim data from Phase 2 clinical trial of JX-594 for HCC at 45th EASL

Smith & Nephew highlights advanced wound care product portfolio at 2010 SAWC/WHS meeting

Healthyroads announces new partnership status with NAQC

Methotrexate therapy not recommended beyond 6 months after remission: JAMA

Potential drug to annul ADAM-17 protein activity needed

Phase II study: Hepatitis C patients receiving ANA598 bid plus SOC attain undetectable levels of virus

Surgery still the only measure to cure RCC

Radiolabeled hedgehog can differentiate stem-like cancer cells, identify aggressive tumors

Results of BATTLE Trial presented at AACR 2010

Cell Therapeutics receives feedback regarding proposed filing of MAA for pixantrone

Data on ConvaTec's medical devices to be presented at SAWC/WHS 2010

Results from Phase 2 study of BOTOX in IOAB patients presented at Anniversary EAU Congress

Enhancing drug residence time may help develop better diagnostic, therapeutic agents

MedImmune to present ten abstracts at American Association for Cancer Research meeting

MEDIHONEY dressings serve as low-cost method for treating wounds in indigent patients

MEDIHONEY dressings effective in treating chronic wounds in children

Access to NAbs testing important for MS therapy management

Extracorporeal liver support therapy valued as detoxification treatment option for patients with cirrhosis

NSF Faculty Early Career Development Award for Zhihao Zhuang

G1 HCV patients having fast antiviral response to TVR with PEG-IFN and RBV can be cured in 24 weeks

Industry Focus eBook - Cell biology (5th edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News